{
    "nctId": "NCT04907344",
    "briefTitle": "Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)",
    "officialTitle": "A Multicenter, Open, Randomized Controlled Study of Camrelizumab+ Nab-paclitaxel + Carboplatin Versus Nab-paclitaxel + Carboplatin as Neoadjuvant Therapy for Triple Negative Breast Cancer (TNBC)",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Triple Negative Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2, PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 420,
    "primaryOutcomeMeasure": "pCR rate using the definition of ypT0/Tis ypN0 (i.e., no invasive residual in breast or nodes; noninvasive breast residuals allowed) at the time of definitive surgery",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Newly diagnosed breast cancer;\n* 18-75 Years, female;\n* ECOG Performance Status of 0-1;\n* Life expectancy is not less than 3 months;\n* Histologically documented TNBC (negative human epidermal growth factor receptor 2 \\[HER2\\], estrogen receptor \\[ER\\], and progesterone receptor \\[PgR\\] status);\n* Tumor stage: II-III;\n* At least one measurable lesion according to RECIST 1.1;\n* Adequate hematologic and organ function.;\n* Must be willing to use an adequate method of contraception for the course of the study.\n\nExclusion Criteria:\n\n* Stage \u2163 (metastatic) breast cancer or bilateral breast cancer;\n* Inflammatory breast cancer;\n* Has received prior any anti-tumor therapy within the past 12 months prior to signing informed consent, including chemotherapy, targeted therapy, radiation therapy, immunotherapy, biotherapy and TACE;\n* Has received prior therapy with an anti-programmed cell death protein 1 (anti-PD-1), anti-programmed death - ligand 1 (anti-PD-L1), or anti-PD-L2 agent or with an agent directed to another co-inhibitory T-cell receptor (e.g., cytotoxic T-lymphocyte-associated antigen-4 \\[CTLA-4\\];\n* Has a history of invasive malignancy \u22645 years prior to signing informed consent except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer;\n* Major surgical procedure within 4 weeks prior to initiation of study treatment;\n* Active or history of autoimmune disease or immune deficiency diseases except history of autoimmune-related hypothyroidism, controlled Type 1 diabetes mellitus;\n* Has a history of (non-infectious) pneumonitis, interstitial lung disease or uncontrollable systematicness diseases;\n* Administration of a live attenuated vaccine within 28 days prior to initiation of study treatment or anticipation of need for such a vaccine during the study;\n* Has a known history of Human Immunodeficiency Virus (HIV);\n* Has known active Hepatitis B, Hepatitis C or Autoimmune hepatitis;\n* Severe infections within 4 weeks prior to initiation of study treatment, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia;\n* Has active infection (CTCAE\u22652) needed the treatment of antibiotic within 2 weeks prior to initiation of study treatment;\n* Has evidence of active tuberculosis within 1year prior to initiation of study treatment;\n* Prior allogeneic stem cell or solid organ transplantation;\n* Pre-existing motor or sensory neuropathy of a severity\u2265grade 2;\n* Has significant cardiovascular disease;\n* Has a known hypersensitivity to the components of the study treatment or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins;\n* Female patients during pregnancy and lactation, fertile women with positive baseline pregnancy tests or women of childbearing age who are unwilling to take effective contraceptive measures throughout the trial;\n* History of neurological or psychiatric disorders, including epilepsy or dementia;\n* Any other situation evaluated by researchers.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}